A Review of the 2024 CCHIO/AOS International Forum I!

A Review of the 2024 CCHIO/AOS International Forum I!

2024.11.18
Adhering to the core concept of "Integrated Cancer Prevention and Treatment, Winning through Integration," on November 14, 2024, a feast of knowledge on cancer prevention and treatment that brought together domestic and international medical elites, patient representatives, and leaders from all walks of life—The 2024 Chinese Congress on Holistic Integrative Oncology and The 40th Anniversary of China Anti-Cancer Association—grandly opened at the Xi'an International Conference Center.
Dr. Jie’er Ying: Exploring New Pathways for Integrative Rehabilitation in Gastric Cancer to Improve Patient Outcomes

Dr. Jie’er Ying: Exploring New Pathways for Integrative Rehabilitation in Gastric Cancer to Improve Patient Outcomes

2024.11.17
The 2024 CACA Integrative Gastric Cancer Conference took place in Wuhan from October 18-19, 2024. Oncology Frontier invited Dr. Jie’er Ying, Chairman of the Chinese Anti-Cancer Association’s Gastric Cancer Integrative Rehabilitation Committee and Head of the Hepatobiliary and Gastric Oncology Department at Zhejiang Cancer Hospital, to discuss the current state and development of integrative rehabilitation for gastric cancer.
AMN 2024| Prof. Wenming Chen Receives AMN Distinguished Achievement Award, Leading China’s Advances in Multiple Myeloma

AMN 2024| Prof. Wenming Chen Receives AMN Distinguished Achievement Award, Leading China’s Advances in Multiple Myeloma

2024.11.16
On October 19, 2024, the 8th Asian Myeloma Network (AMN) Summit was held in Seoul, South Korea. At this event, the International Myeloma Foundation (IMF) hosted the AMN Awards Ceremony. Prof. Wenming Chen from Beijing Chaoyang Hospital, Capital Medical University, received the AMN Distinguished Achievement Award, recognizing his significant contributions to the field of multiple myeloma (MM) and China’s progress in this field. Following the ceremony, Hematology Frontier had the privilege of interviewing Professor Chen. He shared his thoughts on this award, the development of the AMN, and his insights and outlook on the current and future treatment landscape for MM.
ASH 2024 | Prof. Xiaohui Zhang’s Team Presents 11 Groundbreaking Studies with 3 Oral Presentations！

ASH 2024 | Prof. Xiaohui Zhang’s Team Presents 11 Groundbreaking Studies with 3 Oral Presentations！

2024.11.16
The 66th American Society of Hematology (ASH) Annual Meeting will be held from December 7-10, 2024, in San Diego, USA. As the world’s largest and most comprehensive international academic conference in hematology, ASH attracts thousands of experts and scholars from around the globe each year, who come to share cutting-edge developments and breakthrough clinical data. At this year’s conference, Prof. Xiaohui Zhang’s team from the Department of Hematology, Peking University People’s Hospital, and the Institute of Hematology, Peking University, will showcase an impressive total of 11 studies, including three selected for oral presentations, underscoring China’s outstanding achievements in hematology research. This preview highlights these three oral presentations, inviting readers to follow the presentation schedules and learn more about the fascinating details and stories behind these impactful studies.
IHPBA President Interview | Professor René Adam: Exploring Innovative Treatments for CRLM

IHPBA President Interview | Professor René Adam: Exploring Innovative Treatments for CRLM

2024.11.15
October 21-27, 2024, Wuhan, at the 9th Academic Symposium of the Chinese Chapter of the International Hepato-Pancreato-Biliary Association (IHPBA), we interviewed Professor René Adam, the current President of the IHPBA and a famous surgeon at AP-HP Paul Brousse Hospital in Paris, France, to share his research explorations on the use of liver transplantation combined with chemotherapy for the treatment of colorectal cancer with liver metastases (CRLM).
Dr. Zhiyong Ma: Individualized and Duration-Specific Consolidation Therapy for Lung Cancer Patients

Dr. Zhiyong Ma: Individualized and Duration-Specific Consolidation Therapy for Lung Cancer Patients

2024.11.14
The "Expert Consensus on Radiotherapy Combined with Immunotherapy for Unresectable Lung Cancer (2024 Edition)" was recently released under the guidance of Academician Jinming Yu from Shandong Cancer Hospital, Professor Ying Cheng from Jilin Cancer Hospital, and Professor Liang’an Chen from the Chinese PLA General Hospital. This consensus provides evidence and guidance for the application of radiotherapy combined with immunotherapy in clinical practice. In an exclusive interview with Oncology Frontier, Dr. Zhiyong Ma from Henan Cancer Hospital discussed the optimal duration of immunotherapy as consolidation therapy, individualized treatment in radiotherapy combined with immunotherapy, and future research directions.
Balancing Toxicity and Efficacy: How Does Combining ADCs with Other Therapies Impact NSCLC Treatment Prospects?

Balancing Toxicity and Efficacy: How Does Combining ADCs with Other Therapies Impact NSCLC Treatment Prospects?

2024.11.14
For advanced non-small cell lung cancer (NSCLC), treatment strategies typically include platinum-based doublet chemotherapy, immunotherapy, and targeted therapy, with specific methods determined by molecular biomarker testing. Current unmet medical needs for advanced NSCLC patients include a lack of new treatment options following the failure of immunotherapy combinations, resistance to targeted therapies, and strategies to improve efficacy.
CSCO 2024 | Learning from the Past to Guide the Future: How Biomarker Testing Supports Precision Treatment for Lung Cancer

CSCO 2024 | Learning from the Past to Guide the Future: How Biomarker Testing Supports Precision Treatment for Lung Cancer

2024.11.13
The 27th National Clinical Oncology Conference and 2024 CSCO Annual Meeting, co-hosted by the Chinese Society of Clinical Oncology and the Beijing Health Management Development Foundation, took place in Xiamen from September 25-29, 2024. During the conference, several lung cancer-focused forums highlighted cutting-edge research and progress in the field both domestically and internationally. During the event, Oncology Frontier had the opportunity to interview Dr. Tony Mok from the Faculty of Medicine at The Chinese University of Hong Kong. He shared his insights on the current role and future outlook of biomarker testing in clinical practice for lung cancer.